Pancreatitis, Chronic

Seracal™, based on Lym-X-Sorb®, contains a proprietary lipid technology invented by David Yesair Ph.D. and exclusively licensed by Vytala DOWNINGTON, Pa., March 18, 2025 /PRNewswire/ -- Vytala, a healthcare-focused food technology company, today announced a series of key achievements signifying commercial momentum and early market leadership. Following the launch of Seracal in November, monthly sales growth has exceeded 50%, driven by strong clinician interest, patient need, and broad coverage by US healthcare insurers. Continue Reading Seracal Logo (PRNewsfoto/Vytala) Dr. Debora Duro, Program Director, Pediatric Gastroenterology, Hepatology and Nutrition at Broward Health, has prescribed Seracal to multiple patients and shares: "Seracal is amazing. I have patients with diagnoses ranging from intestinal failure to faltering weight, and most have experienced weight gain within the first month. Parents are overjoyed, the product is easy to use, and children are gaining weight after months of struggle." Market demand for Seracal has surpassed initial forecasts with a 90% reorder rate – further confirming strong patient acceptance and sustained clinical adoption. Seracal was recently approved by 3 HealthWell Foundation disease funds within Vitamins and Supplements*. This partnership expands access and provides support for patients starting on their Seracal journey. Seracal is an improved formulation that contains the underlying technology of Lym-X-Sorb, a pioneering nutritional therapy invented by Dr. David Yesair of BioMolecular Products, Inc. that addresses fat malabsorption. Seracal/Lym-X-Sorb was proven to be efficacious and well-tolerated in patients with exocrine pancreatic insufficiency and cystic fibrosis in a large $7 million National Institutes of Health sponsored clinical study. Subjects randomized to Seracal/Lym-X-Sorb experienced improved BMI, as demonstrated by increases in both weight and height velocity. The therapy also improved absorption of essential fatty acids, fat-soluble vitamins and choline. Vytala signed an exclusive worldwide licensing agreement with BioMolecular Products (BMP), gaining rights to Lym-X-Sorb's proprietary formulation and extensive manufacturing trade secrets. Over $30 million dollars has funded development of the Lym-X-Sorb technology to date. Vytala has made further formulation enhancements, incorporating key taste, texture and stability improvements into Seracal. A patient with pancreatic cancer describes his experience with Seracal: "I have gained between 8-10 pounds since starting Seracal 6 weeks ago. I believe it has also helped with my chronic pancreatitis, lessening the symptoms of belly pain and back pain. This has allowed me to widen my diet to include foods that I couldn't eat previously." Vytala is actively enrolling subjects into an IRB approved study designed to assess Seracal's acceptance and clinical outcomes across a broader patient populations. Led by Dr. Carol Ireton-Jones PhD, RDN, CNSC, FASPEN, FAND, an esteemed expert in gastrointestinal nutrition with numerous publications - the multi-center study will measure GI symptoms, weight gain and nutrient absorption in at least 30 patients aged one and older. Swapna, a healthcare advocate, researcher and adult living with Short Bowel Syndrome, conveyed her excitement about being one of the first patients to enroll in the study: "Living a fulfilling life with tube feeding due to congenital Short Bowel Syndrome, I have always had to be at the mercy of innovation. Participating in Vytala's early experience program, I can finally be at the forefront of science. I hope Seracal will be the easy and accessible answer to my reduced ability to absorb fat and fat-soluble nutrients, a barrier I have had for 35 years. Maybe I can even live to eat and enjoy nourishing myself with food without all the complications! A goal I have only dreamed of." Dr. Ireton-Jones commented, "Anecdotal data provides insight into patient experiences, but in the scientific community, research is essential to generate evidence. That is why we're conducting this study. We are confident that Seracal's unique technology will improve fat absorption in patients with a variety of GI conditions, which is why this study is so important." Seracal is available nationwide and is covered by most healthcare insurers. *Approved for Alagille Syndrome, Cystic Fibrosis, and Inborn Errors and Genetic Bile Acid Deficiency About Vytala Vytala is advancing nutrition with a mission to help people achieve their best health through the power of nutrition. Our founding team is committed to addressing the widespread problem of malabsorption and brings over 100 years of experience in clinical nutrition, food science, healthcare and in reimbursement. Vytala's unique crystalized lipid technology has been proven in multiple clinical studies, and CMS has issued a new reimbursement code for the product. Vytala is developing a suite of precision nutrient products to address a broad spectrum of diseases in humans and animals. The company will not rest until it has eliminated nutrient deficiencies. SOURCE Vytala WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range of strategic business initiatives and has represented numerous companies in both private and public offerings of debt and equity securities, comprehensive understanding of capital markets and regulatory environments. His advisory work has been pivotal to several successful M&A and go-public transactions. In addition to his transactional work, Mr. Paolone has built a reputation as a trusted advisor to management teams and boards, ensuring legal and regulatory compliance in Canada while facilitating business growth. His broad experience also includes serving as a director or officer for several private and publicly traded companies, where he continues to provide strategic insights and governance expertise to help guide their success in competitive markets. For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn. About Entero Therapeutics Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com. For more information:Entero Therapeutics, Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561) 589-7020info@enterothera.com Investor contact information:Entero Investor Relationsinvestors@enterothera.com

LOS ANGELES, Dec. 18, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid biopsy screening test that aids in the detection of Pancreatic Ductal Adenocarcinoma (PDAC) in people with elevated risk. The test uses a simple blood sample, next-generation sequencing, and a proprietary machine learning pipeline to analyze levels of microRNA and CA19-9 biomarkers. In January of 2024, PharusDx entered into an exclusive global licensing agreement with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with a Los Angeles comprehensive cancer center ranked among the nation's top 5 cancer centers by U.S. News & World Report, for a proprietary panel of microRNA (miRNA) biomarkers with testing data demonstrating potential value for early detection of PDAC. OncoSweep™ Pancreas Spotlight builds on the biomarker panel and approach from City of Hope, moving the translational academic findings into a Laboratory Developed Test (LDT). This effort leverages PharusDx's OncoSweep™ liquid biopsy platform and City of Hope's groundbreaking early cancer detection research led by Dr. Ajay Goel, Chair of City of Hope's Department of Molecular Diagnostics and Experimental Therapeutics. "We have been hard at work validating our pancreatic cancer miRNA biomarker panel and have now completed CLIA[1] LDT validation of our test, an exciting milestone for the company and people at-risk who have limited options for early detection of this devastating disease" explained CEO Philip Huang. "We are thrilled to bring this potentially life-saving technology developed by PharusDx, based on translational research findings from City of Hope, to market," said Bowei Lee, Chairman of PharusDx. "An accurate early detection tool can significantly improve outcomes for people with PDAC, particularly when surgical intervention remains a viable option." Combating a Deadly Disease PDAC is an aggressive form of cancer with a dismal prognosis. Due to its location within the body and lack of early symptoms, the disease is often diagnosed at an advanced stage, significantly reducing survival rates. Most PDAC is detected at stage IV when there is just a 3%[2],[3] five-year survival rate. If the disease is caught at stage I, the five-year survival jumps to over 40%[2], a greater than 10-fold increase. Those at increased risk for PDAC include people with Lynch syndrome, Peutz-Jeghers syndrome, new-onset diabetes (after 50 yrs old), pancreatic cysts, chronic pancreatitis, certain mutations in BRCA1/2, PRSS1, ATM, TP53, those with first degree relatives as well as those with certain lifestyle risk factors such as smoking, alcohol abuse, or obesity. A Brighter Future for Patients PharusDx's new OncoSweep™ Pancreas Spotlight LDT has the potential to significantly improve outcomes by offering a non-invasive and accurate screening method for early-detection. The development of this LDT, in conjunction with PacificDx (a CLIA-accredited laboratory) in Irvine, California, aligns with PharusDx's commitment to advancing early cancer detection. By offering a simple blood test for PDAC, the company aims to empower individuals at risk for the disease to undergo regular monitoring to detect early-stage disease when they have the most options for treatment. References and Notes About PharusDx PharusDx is at the forefront of healthcare innovation, specializing in advanced diagnostic technologies. Founded in 2022, our mission is to detect cancer early to help provide more treatment options and improve patient outcomes. Our focus is to create exceptionally precise and accurate tests by integrating liquid biopsies, advanced biomarkers and machine learning. OncoSweep™ early detection tests are designed to be convenient and accessible, with the patient always at the center. For more information on PharusDx visit or connect on LinkedIn: For media/investor inquiries/partnership, please contact: [email protected] Conflict of Interest Statement: Dr. Goel is a compensated PharusDX advisory board member and as an inventor of the technology licensed to the company by City of Hope, is entitled to royalty payments from the company. SOURCE Pharus Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED